IP Library › Granted Patent US 9,499,462
Granted Patent B2
US 9,499,462 · App. 13/983,430 · Granted Nov 22, 2016

Isolated compounds from turmeric oil and methods of use

Inventors: Gilbert M. Rishton (Los Angeles, CA); Susan Catalano (Pittsburgh, PA)
Assignee: Cognition Therapeutics, Inc.
C07C33/20C07C33/14C07C33/26C07C33/30C07C211/27C07C215/26C07C215/28C07B2200/07C07C2101/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,462
App. No.
13/983,430
Granted
Nov 22, 2016
Kind
B2
Abstract

Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.

Claims (41)

1. A compound comprising formula I-0

or pharmaceutically acceptable salt thereof, wherein:

is selected from a single bond and a double bond;

R 1 is selected from F, Cl, Br, CF 3 , and OCF 3 ;

R 2 is selected from CH 2 C(CH 3 ) 2 OH and CH═C(CH 3 ) 2 ; and

R 3 is NHCH 2 CH(CH 3 ) 2 .

2. The compound of claim 1 , wherein R 2 is CH 2 C(CH 3 ) 2 OH.

3. A compound comprising formula I-1

or pharmaceutically acceptable salt thereof, wherein:

is selected from a single bond and a double bond;

R 1 is selected from F, Cl, Br, CF 3 , and OCF 3 ;

R 2 is selected from CH 2 C(CH 3 ) 2 OH and CH═C(CH 3 ) 2 ; and

R 3 is NHCH 2 CH(CH 3 ) 2 .

4. A compound comprising formula I-2

or pharmaceutically acceptable salt thereof, wherein:

is selected from a single bond and a double bond;

R 1 is selected from F, Cl, Br, CF 3 , and OCF 3 ;

R 2 is selected from CH 2 C(CH 3 ) 2 OH and CH═C(CH 3 ) 2 ; and

R 3 is NHCH 2 CH(CH 3 ) 2 .

5. The compound of claim 4 , wherein R 2 is CH 2 C(CH 3 ) 2 OH.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-0

wherein:

is selected from a single bond and a double bond;

R 1 is selected from F, Cl, Br, CF 3 , and OCF 3 ;

R 2 is selected from CH 2 C(CH 3 ) 2 OH and CH═C(CH 3 ) 2 and

R 3 is NHCH 2 CH(CH 3 ) 2

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-1

wherein:

is selected from a single bond and a double bond;

R 1 is selected from F, Cl, Br, CF 3 , and OCF 3 ;

R 2 is selected from CH 2 C(CH 3 ) 2 OH and CH═C(CH 3 ) 2 ; and

R 3 is NH CH2 CH(CH3) 2

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-2

wherein:

is selected from a single bond and a double bond;

R 1 is selected from F, Cl, Br, CF 3 , and OCF 3 ;

R 2 is selected from CH 2 C(CH 3 ) 2 OH and CH═C(CH 3 ) 2 ; and

R 3 is NHCH 2 CH(CH 3 ) 2

or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2016
From: RISHTON, GILBERT M.; CATALANO, SUSAN
To: COGNITION THERAPEUTICS, INC.
Reel/Frame 039110/0359 →
Continuity (2)
Provisional Application 61438916 · Feb 2, 2011
Related Publication 20140080916A1 · Mar 20, 2014